drugset / Trial / NCT04903184

Exploratory Study to Evaluate the Efficacy of RUTI® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers

NCT04903184 ↗

Phase 2 Completed 251 enrolled RUTI Immunotherapeutics S.L.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The aim of this study is to explore potential for reduction of incidence and/or morbidity of SARS-CoV-2 infection in healthcare personnel. The study will include a comparison between placebo and RUTI® vaccine in a 2:1 design.

Timeline

Start
2021-01-06
Primary completion
2021-11-11
Completion
2021-11-11

Drugs

EvaluationDrugModalityDoseRoute
Subject RUTI® Vaccine 25 ug Subcutaneous

Indications